Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-ASCO & EHA 2024 MDS Highlights
02 July 2024 | Virtual Meeting
Presentation summaries of key MDS abstracts from ASCO & EHA 2024 featuring panel discussions with leading experts
The Post-ASCO & EHA 2024 MDS Highlights was supported by Bristol Myers Squibb and Genentech. Supporters have no influence over the production of content.
Latest in low- and lower-risk MDS
Durable clinical benefit with elritercept treatment in lower-risk MDS
María Díez Campelo University of Salamanca, Salamanca, Spain
IMerge: OS, clinical benefit, and durable TI with imetelstat in lower-risk MDS
Valeria Santini University of Florence, Florence, Italy
Comparative biomarker analysis from the COMMANDS study: Luspatercept in lower-risk MDS
Uwe Platzbecker University Hospital Carl Gustav Carus, Dresden, Germany
Session 1 panel discussion
Novel treatment approaches in high-risk MDS & therapy-related MDS
IDIOME: Ivosidenib monotherapy in IDH1 mutated MDS
Marie Sebert Saint-Louis Hospital, Paris, France
STIMULUS-MDS2: sabatolimab + AZA vs PBO + AZA for HR MDS or CMML-2
Amer Zeidan Yale University School of Medicine and Yale Cancer Center, New Haven, CT, United States
ENHANCE: Magrolimab + AZA vs PBO + AZA for high-risk MDS
David Sallman H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
Session 2 panel discussion
Advances in prediction and assessment of treatment responses and outcomes
Impact of complete cytogenetic responses in patients with MDS
Samuel Urrutia Washington University School of Medicine, St. Louis, MO, United States
Validation of IWG-2023 response criteria
Lisa Pleyer Paracelsus Medical University, Salzberg, Austria
ENHANCE: Magrolimab + AZA vs PBO + AZA for high-risk MDS
Anne Sophie Kubasch University of Leipzig, Leipzig, Germany
Questionable benefit of prior therapy in MDS pts undergoing allo-SCT
Christof Scheid University Hospital Cologne, Cologne, Germany
VALIDATE: PB-CR is associated w. similar survival as CR per IWG 23 criteria
Jan Bewersdorf Yale Cancer Center, New Haven, CT, United States
Session 3 panel discussion
Supported by:
Gold Supporters
Silver Supporters
